Drug Testing in vitro

Foreword (Rolf Krebs)

Preface

List of Contributors

PART I EMERGING IN-VITRO CULTURE TECHNOLOGIES

Intelligent Biomatrices and Engineered Tissue Constructs: In-Vitro Models for Drug Discovery and Toxicity Testing (Philip Lazarovici, Mengyan Li, Anat Perets, Mark J. Mondrinos, Shimon Lecht, Christopher D. Koharski, Paul R. Bidez III, Christine M. Finck, and Peter I. Lelkes)

An Overview on Bioreactor Design, Prototyping and Process Control for Reproducible Three-Dimensional Tissue Culture (Ralf Pörtner and Christoph Giese)

An Overview on Bioelectronic and Biosensoric Microstructures Supporting High-Content Screening in Cell Cultures (Andrea A. Robitzki and Andrée Rothermel)

Novel In-Vitro Exposure Techniques for Toxicity Testing and Biomonitoring of Airborne Contaminants (Amanda Hayes, Shahnaz Bakand, and Chris Winder)

PART II PRIMARY TISSUES AND CELL LINES IN DRUG SCREENING/TESTING

Drug Screening Using Cell Lines: Cell Supply, High-Throughput and High-Content Assays (Christa Burger, Oliver Pöschke, and Mirek R. Jurzak)

Cell Lines and Primary Tissues for In-Vitro Evaluation of Vaccine Efficacy (Anthony Meager)

Designer Cells Derived from Primary Tissue and Designed Cell Lines as a Sustainable Cell Source for Drug Discovery and Safety Assessment (Volker Sandig and Ingo Jordan)

How Human Embryonic Stem Cell Research Can Impact In-Vitro Drug Screening Technologies of the Future (André Schrattenholz and Martina Klemm)

PART III THE USE OF HUMAN TISSUES IN DRUG DISCOVERY: SCIENTIFIC, ETHICAL, LEGAL, AND REGULATORY ENVIRONMENTS

Availability, Standardization and Safety of Human Cells and Tissues for Drug Screening and Testing (Glyn N. Stacey and Thomas Hartung)

Ethical Environment and Scientific Rationale Towards In-Vitro Alternatives to Animal Testing: Where Are We Going? (Horst Spielmann)

PART IV SUMMARY AND VISIONS

How Drug Development of the 21st Century Could Benefit from Human Micro-Organoid In-Vitro Technologies (Uwe

Dr. Uwe MarxAfter finishing medical training Uwe Marx received his doctoratedegree in immunology from the Humboldt University, Berlin. In 1995 Dr. Marx was appointed Head of the Department of Medical Biotechnology at Leipzig University and joined ProBioGen, Berlin, in 2000 as Chief Scientific Officer.With more than 20 years of experience in protein drug development and improvement of cell culture techniques, Uwe Marx has published more than 50 scientific papers and holds numerous patents.Dr. Volker SandigVolker Sandig studied medicine and received his PhD in molecular biology from the Humboldt University, Berlin. He designed experimental strategies for adenovirus based tumor treatment and directed research projects in cell cycle regulation and artificial promoters at the Max Planck Society and Hepavec, a former Berlin-based biotech company. He then joined Merck Research Laboratories, USA and was appointed Vice President Molecular Biology and Virology at ProBioGen, Berlin, Germany in 2000.

"...highly topical handbood..."Anticancer Research